Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, Six-Way Crossover Study Evaluating the Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug- Dependent, Recreational Opioid Users

NCT07813026 is registered in ClinicalTrials.gov with Viatris Inc. as lead sponsor.

NCT NCT07813026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07813026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, Six-Way Crossover Study Evaluating the Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug- Dependent, Recreational Opioid Users
Lead sponsor
Viatris Inc.
Phase
Phase 4
Overall status
Recruiting
Start date
August 3, 2026
Completion date
February 14, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, non-drug- dependent, recreational opioid users